Announced ITF 4 August: Tan Delta Systems plc, a Sheffield based Company intends to IPO on AIM. Tan Delta has developed an innovative and differentiated monitoring solution based on real time oil analysis and analytics that offers equipment operators enhanced insight into the maintenance status of their equipment and thus the ability to reduce maintenance costs, improve reliability and reduce carbon footprint. Anticipated Market Cap £19m. Capital to be raised on Admission: £6.0m via primary proceeds and £0.57m via secondary sale of existing ordinary shares. Admission expected 18 August 2023.
Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market.
Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
Andrada Mining 7p £107.7m (ATM.L)
The African technology metals mining company with a portfolio of mining and exploration assets in Namibia, provides an update on the previously proposed Funding Package with funds managed by Orion Resource Partners announced on 15 September 2022. On 11 August 2023, Andrada signed binding documentation for an updated, conditional US$25m funding package with Orion. The financing agreement is as follows: US$2.5m (c£2.0m) equity at 6.39p and US$10m (c£7.9m) Convertible Loan Note being for the general purposes of accelerating Andrada's overall strategy of achieving commercial production of its lithium, tin, and tantalum revenue streams. US$12.5m unsecured tin royalty to increase tin production. The Company will issue Orion with warrants equivalent to double the GBP value of the US$10m Convertible Loan Note based on the USD/GBP closing rate at market close on the Orion Issuance Date. Each warrant will enable Orion to subscribe for one ordinary share in the Company. Funding expected to be completed around the end of September 2023, with shareholder approval.
Ariana Resources 2.6p £29.8m (AAU.L)
The mineral exploration and development company with gold mining interests in Europe, announces the results of recent exploration and development work conducted at Kiziltepe. The Kiziltepe Project is operated via Zenit Madencilik San. ve Tic. A.S. in partnership with Proccea Construction Co. and Ozaltin Holding A.S. and is 23.5% owned by Ariana. Recent drilling undertaken has defined the likely economic limits of the known vein systems. Drilling remains underway at Karakavak, with progression onto Kepez and with a separate programme ongoing at Kizilcukur. Targets defined following a recent Induced Polarisation (IP)/Resistivity survey will become the focus of further drilling across the Kiziltepe Sector. Opportunities to further extend mine life to nine years, through to 2025, and potentially beyond are being assessed.
Empresaria Group 40.5p £20.2m (EMR.L)
The global specialist staffing group, announces the launch of its Professional service offering, LMA Recruitment, in the United States. LMA Recruitment in the US will initially target HR, business support, sales, marketing and operational skillsets. The launch follows a global rebrand of LMA Recruitment, Empresaria's lead Professional brand with offices in the UK and Singapore. The US was chosen as the first market for LMA's expansion due to demand for Professional staffing from existing clients of the Group's well-established IT and Healthcare operations within the US. The launch is part of Empresaria's medium-term growth plans focused around three key pillars: accelerating growth in high potential sectors, diversifying its service offering and growing Offshore Services.
Evgen Pharma 2.65p £7.3m (EVG.L)
The clinical stage drug development company developing sulforaphane-based medicines, reports the final data from its Phase 1b healthy volunteer study using the Company's new enteric coated tablet formation of lead asset SFX-01. The data are contained in the extensive Clinical Study Report (CSR) which has been approved by the Company and its providers in compliance with good clinical practice (GCP). The final CSR confirms that the new formulation of SFX-01 is safe and well tolerated at multiple doses. As reported in March 2023, based on the time course seen, sulforaphane was released by the new enteric coated tablet beyond the acid environment of the stomach. No serious adverse events were observed. Total blood levels of sulforaphane (SFN) and SFN-metabolites were confirmed in the micromolar range, where efficacy is seen in vitro. Additional pharmacodynamic exploratory investigation, utilising mRNA sequencing, showed changes in gene expression after dosing with SFX-01 even in healthy volunteers.
Gelion 24.5p £26.6m (GELN.L)
The Anglo-Australian battery innovator, provides an update on the Group's trading for the year ended 30 June 2023. Revenues for the year are expected to be £2.0m ahead of current guidance of £1.7m. Adjusted EBITDA loss is expected to be approximately £6.0m, lower than guidance of £6.4m. Net cash at 30 June 2023 was £7.3m. Since March 2023, the Company has been focused on reducing costs and has reduced cash consumption by c. £1.0m on an annualised basis. Gelion also announces the signing of two agreements with The University of Sydney and Professor Yuan Chen for Gelion's Advanced Cathode Project, accelerating progress towards its Zinc-based Energy Storage Solution. The agreements are to utilise Gelion's recent zinc anode performance leading to Gelion's next generation of energy solutions - Gelion's Gen 5 Zinc Hybrid Cell.
Instem 602.5p £138m (INS.L)
The provider of IT solutions to the global life sciences market, announces a trading update for the six months to 30 June 2023. Revenue is expected to be £29.7m (H1 2022: £27.0m), an increase of approximately 10.2%, with recurring software revenue growing by 27%. This excludes Samarind Limited, which was sold on 1 April 2023 and will be classified as a discontinued operation in the H1 2023 results statement. Annual Recurring Revenue at 1 July 2023 was c.£41m (1 July 2022: £32m). Closing cash at 30 June 2023 was £8.4m (30 June 2022: £10.3m). During the period, Instem announced the transfer of the ToxHub Platform and launch of Centrus. The Company also renewed its long-standing agreement with the National Toxicology Program. Management is confident performance will be broadly in line with the Board's expectations for the full year.
MTI Wireless Edge 41p £36.2m (MWE.L)
The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors, announces its financial results for the six month period ended 30 June 2023. Revenues of US$22.4m (H1 22: US$22.7m), held back by adverse currency translation. On a constant currency basis revenues increased by 2%. Gross margin improved 1% to 32% (H1 22: 31%) and profit before tax increased 3% to US$2.1m (H1 2022: US$2.04m). Earnings per share increased 9% to 1.99 US cents (H1 2022: 1.83 US cents) and net cash provided by operating activities improved to US$1.23m (H1 2022: US$0.037m). Net cash at 30 June 2023 to $6.25m (30 June 2022: $5.18m).
TMT Investments* 300c $94.4m (TMT.L)
The venture capital company investing in high-growth technology companies announces its unaudited interim results for the half-year ended 30 June 2023. NAV per share of US$6.32, representing a 1.4% decrease from US$6.41 as of 31 December 2022. Total NAV of US$198.7m (US$201.7m as of 31 December 2022). During the period, TMT invested US$2.4m across six new and existing companies. TMT’s largest holdings (Bolt, Backblaze, PandaDoc, 3S Money and Scentbird) continued to perform well, recording double-digit annualised revenue growth. As of 14 August 2023 the Company reported US$7.8m in cash and cash equivalent reserves (including treasury bills) and no financial debt. TMT is well positioned to ride out the current market volatility and to continue investing in growth companies.
UP Global Sourcing Holdings 128p £115.2m (UPGS.L)
The owner of a number of homeware brands including Salter announces its trading update for the financial year ended 31 July 2023 (FY23). Unaudited Group revenues increased 8% to a record £166.3m (FY22: £154.2m), driven by growth at the Group's online division, where revenues were up 64% year-on-year, together with an improved sales mix. Unaudited adjusted EBITDA increased 8% to £20.2m (FY22: £18.8m) and unaudited adjusted PBT increased 6% to £16.8m (FY22: £15.8m). At the year end, the Group had a net bank debt of £14.8m (FY22: £24.3m). Current trading for FY24 is in line with market expectations.
Verditek 1.2p £5.3m (VDTK.L)
The international green technology company announces it has signed a non-binding Memorandum of Understanding (MOU) that forms the basis of the framework for a 50:50 Joint Venture Agreement (JVA) with Net Zero Valley (NZV), an Italian fully owned investment holding of the SerendipEquity Group, a global impact/ESG-only private equity and real estate investment firm and alternative fund manager, to invest in a new large scale (1GW) ultra-lightweight solar panel manufacturing plant in Southern Italy on NZV's 1.5m sq ft campus. NZV is planning to establish an integrated R&D and manufacturing campus in Eastern Sicily which will focus on technologies for the decarbonisation of the real estate and automotive sectors and systemic solutions and applications thereof. Verditek will be responsible for providing its expertise in sourcing the required machinery, setting up and operating the plant, deploying its proprietary know-how and ensuring the 1GW factory is certified. Verditek will be jointly responsible for securing for the new JV its existing strategic distribution partners that already sell photovoltaic integrated roof products as well as new prospective off-takers.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
